SEER

Insider Trades

Name	Value	Action	Price	Current Price
Horn David R.PRESIDENT & CFO $12k7.3k shares SellMay 20, 2026 $1.69 --
Horn David R.Insider $12k7.3k shares SellMay 20, 2026 $1.69 --
Farokhzad OmidDirector, Officer: CEO AND CHAIR $49k24.4k shares SellFeb 18, 2026 $1.99 --
Horn David R.PRESIDENT & CFO $15k7.7k shares SellFeb 18, 2026 $1.99 --
Farokhzad OmidDirector, Officer: CEO AND CHAIR $67k33.8k shares SellNov 19, 2025 $1.97 --
Horn David R.PRESIDENT & CFO $13k6.8k shares SellNov 19, 2025 $1.97 --

News

businesswire.comThe Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destructionbusinesswire.comJun 15

globenewswire.comSeer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaignglobenewswire.comJun 15

globenewswire.comSeer Files Definitive Proxy Materials and Mails Letter to Stockholdersglobenewswire.comJun 3

gurufocus.comEncouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026gurufocus.comMay 30

globenewswire.comSeer Files ITC Complaint Against Nanomicsglobenewswire.comMay 29

Trade SEER

About Seer, Inc.

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

CEO: Omid C. Farokhzad
IPO Date: Dec 4, 2020

Market Data

Open: $1.72
High: $1.74
Low: $1.71
Volume: 83.1K
Avg Volume: 322.4K
52W High: $2.41
52W Low: $1.65

Valuation

Market Cap: $96M
Enterprise Value: $71M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-46M
Revenue: $16M
Net Income: $-74M
Cash: $47M
Debt: $24M

Events

EarningsAug 5

EPS est. -0.215